Ipsen, a French bio-pharmacy company, launched its first regional office in the Middle East and Africa (MEA) in Dubai, with the goal of establishing direct operations and bringing innovative medicines to the region’s unmet medical needs in oncology, rare diseases, and neurology.
The company claimed that its new office at the Al Jalila Foundation building will enable it to begin direct operations and bring treatment to meet demands in oncology, rare diseases, and neuroscience.
Dr. Amin Hussain Al Amiri, assistant undersecretary of Health Regulations Sector at the UAE Ministry of Health and Prevention (MoHAP), said, “Ipsen’s commitment to investing in the UAE and the region, and its decision to open its regional headquarters here is a welcome step that further underlines our nation’s rich legacy of facilitating the regional expansion of multinational firms.”
The UAE has emerged as a global pharmaceutical hub led by an exceptional healthcare and business infrastructure, and a strong legislative environment that supports innovative and international-standard healthcare enterprises.
“The opening of our new office in Dubai is a milestone for our company. We look forward to building value through our global innovation in oncology, rare diseases and neuroscience, as we strive to contribute to the health and well-being of the people of the UAE, and the region, especially at a time when healthcare is top priority.”
Ipsen Group recorded net sales of more than $2.9 billion in 2020, marking a 3 percent increase in sales. The company raised its R&D investments, which now account for 15.6 percent of net sales, and has made great progress in developing a rare disease franchise for the next decade. The company sells 20 different medicines and operates in over 30 countries, with research facilities in France, the United Kingdom, the United States, and China.
The pharmaceutical industry is one of 11 key hubs by the UAE government as development targets as part of the Operation 300 billion strategy announced this year, which aims to boost the industrial sector’s contribution to GDP from $36.2 billion to $81.6 billion currently.